Patients Report Fewer Moderate and Serious Side Effects with IMRT Than With Brachytherapy for Treatment of Low-Risk Prostate Cancer
PHILADELPHIA -In one of the first studies to compare side effects of IMRT and permanent prostate brachytherapy (I-125) for treatment of low-risk prostate cancer, researchers say patients had fewer moderate and serious side effects when treated with IMRT. The study results were presented today at the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology in Philadelphia.
"Both treatments demonstrated excellent PSA outcomes (biochemical control) after treatment," said Thomas N. Eade, MBChB, a fellow in the department of radiation oncology at Fox Chase Cancer Center. "The patients who received IMRT tended to be older, but even with that factor, IMRT was better tolerated." PSA, or prostate specific antigen, is measured by a blood test and used to determine if prostate cancer is present.
The study included 374 patients with low-risk prostate cancers treated at Fox Chase with either IMRT (216 patients) or I-125 seed brachytherapy (158 patients). Patients who received neoadjuvant hormones were excluded from the study. The IMRT dose ranged from 74 to 78 Gy. The implant dose was 145 Gy. IMRT patients were an average of three years older (median age 67.6 years compared to 64.7 years).
Serious long-term side effects were significantly higher in the I-125 patients, including urethral stricture (narrowing) and catheterization. Catheterization within the first three months was required in three of the IMRT patients and 11 of the I-125 patients. Only one IMRT patient and seven of the implant patients required catheterization more than three months after completing treatment.
"There are limited studies looking at long-term outcomes in IMRT as it is a relatively new technology," said Eade. "However, Fox Chase has been a leader in this area and is one of the only institutions that can investigate this question."
"This study shows men treated with brachytherapy have an increased risk of long-term side effects with brachytherapy as compared to IMRT," Eade said. "Advances in technologies will continue to improve outcomes for both treatment modalities, but for now IMRT delivers excellent cancer control with fewer long-term problems."
Fox Chase Cancer Center, part of Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase also was among the first institutions to receive the National Cancer Institute’s prestigious comprehensive cancer center designation in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are routinely recognized in national rankings, and the Center’s nursing program has achieved Magnet status for excellence three consecutive times. Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research and oversees programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX-CHASE (1-888-369-2427).